background
pandem
specif
antivir
treatment
vaccin
urgent
need
explor
neutral
antibodi
patient
differ
clinic
characterist
emerg
total
blood
sampl
collect
inpati
convalesc
patient
presenc
neutral
antibodi
determin
modifi
cytopathogen
assay
base
live
dynam
neutral
antibodi
level
differ
differ
clinic
characterist
analyz
result
seroposit
rate
reach
within
day
sinc
onset
remain
till
day
total
gmt
ci
antibodi
level
highest
day
sinc
onset
decreas
slightli
individu
differ
chang
antibodi
level
observ
among
repres
convalesc
patient
multivari
gee
analysi
patient
age
higher
antibodi
level
age
patient
wors
clinic
classif
higher
antibodi
titer
conclus
neutral
antibodi
detect
even
earli
stage
diseas
signific
respons
show
convalesc
patient
moreov
chang
antibodi
level
ware
individu
specif
famili
coronavirida
compris
larg
envelop
singlestrand
positivesens
rna
virus
infect
wide
rang
anim
human
two
coronaviru
pandem
human
emerg
past
two
decad
sever
acut
respiratori
syndrom
coronaviru
sarscov
first
recogn
caus
global
outbreak
follow
anoth
pandem
event
design
middl
east
respiratori
syndrom
coronaviru
merscov
decemb
emerg
sever
acut
respiratori
syndrom
coronaviru
origin
wuhan
china
rapidli
spread
worldwid
world
white
blood
cell
count
obtain
indic
immunogen
assess
includ
seroposit
rate
determin
geometr
mean
titer
gmt
neutral
antibodi
titer
calcul
reedmuench
method
day
titer
higher
indic
seroposit
calcul
gmt
antibodi
titer
assign
valu
respect
presenc
neutral
antibodi
determin
modifi
cytopathogen
assay
serum
sampl
inactiv
minut
serial
dilut
cell
cultur
medium
twofold
step
dilut
serum
mix
viru
suspens
plate
ratio
follow
hour
incub
co
incub
vero
cell
ad
serumviru
mixtur
plate
incub
day
co
incub
cytopath
effect
cpe
well
record
microscop
neutral
titer
calcul
dilut
number
protect
condit
funder
role
studi
design
data
collect
data
analysi
data
interpret
write
report
patient
enrol
studi
recov
discharg
hospit
tabl
mean
age
patient
year
rang
total
femal
among
patient
resid
travel
wuhan
hubei
number
patient
histori
cardiovascular
diseas
diabet
hypertens
respect
one
patient
asymptomat
infect
mild
clinic
manifest
moder
remain
sever
condit
inpati
convalesc
patient
circul
creactiv
protein
inpati
convalesc
patient
seroposit
rate
reach
blood
sampl
differ
stage
ill
total
gmt
ci
titer
tabl
analyz
chang
antibodi
level
accord
time
cours
sinc
onset
tabl
antibodi
level
accord
differ
time
cours
sinc
onset
significantli
differ
gmt
day
sinc
onset
ci
reach
highest
decreas
slightli
time
period
univari
gee
analysi
show
antibodi
level
day
significantli
higher
phase
tabl
howev
multivari
gee
analysi
show
antibodi
level
day
higher
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
tabl
due
wide
spread
around
world
specif
therapeut
agent
vaccin
urgent
need
analyz
neutral
antibodi
level
among
differ
classif
patient
increas
day
sinc
onset
symptom
result
indic
signific
neutral
antibodi
respons
observ
convalesc
patient
moreov
individu
differ
chang
antibodi
level
studi
typic
antibodi
respons
live
viral
infect
seen
induc
patient
regardless
stage
diseas
moreov
immun
level
alreadi
strong
enough
even
earli
stage
ill
seroposit
rate
reach
day
gmt
reach
peak
day
onset
symptom
even
though
gmt
slightli
decreas
day
seroposit
rate
remain
howev
result
differ
studi
indic
titer
antibodi
reach
peak
day
diseas
onset
adjust
cofound
factor
multivari
gee
analysi
demonstr
antibodi
level
compar
day
day
sinc
diseas
onset
howev
proport
titer
decreas
day
day
due
lack
blood
sampl
collect
patient
later
stage
ill
whether
seroposit
rate
declin
remain
unknown
long
immun
patient
last
key
big
unknown
problem
safe
effect
antivir
treatment
vaccin
futur
coronavirus
immun
infect
strong
sever
month
began
wane
chang
indic
peak
igg
titer
sarscov
patient
appear
month
month
diseas
onset
drop
averag
igg
titer
evid
month
month
onset
studi
suggest
worthi
studi
analyz
antibodi
patient
recov
longer
time
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
thank
local
health
worker
local
cdc
profession
contribut
field
investig
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
data
express
specifi
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
b
p
valu
gmt
calcul
use
kruskalw
ranksum
nonparametr
method
b
p
valu
proport
titer
less
calcul
use
trend
chisquar
test
c
p
valu
proport
titer
calcul
use
chisquar
test
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
p
valu
gmt
calcul
use
kruskalw
ranksum
nonparametr
method
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
figur
b
c
e
f
g
h
repres
repres
convalesc
patient
figur
four
patient
whose
antibodi
titer
show
obviou
increas
trend
includ
figur
b
includ
four
patient
whose
antibodi
titer
show
decreas
trend
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
